BioCryst, Green Cross to develop influenza neuraminidase inhibitor in Korea

By Lisa Kerner

Charlotte, N.C., June 14 - BioCryst Pharmaceuticals, Inc. and Green Cross Corp., a South Korean biotechnology company, have agreed to develop and commercialize BioCryst's influenza neuraminidase inhibitor, peramivir, in Korea.

Under the agreement, Green Cross will conduct clinical trials in South Korea, which are in addition to BioCryst's planned studies in the United States, Europe, Thailand, Vietnam and Indonesia.

Green Cross will also pay a one-time license fee, milestone payments and royalties to BioCryst, according to a company news release.

Both companies will share in any profits from sales to the Korean government for stockpiling of peramivir.

Peramivir inhibits influenza viral neuraminidase, an enzyme essential for the influenza virus to spread and infect its hosts. It is a selective inhibitor of influenza A and B neuraminidases and has shown activity against H5N1 avian influenza.

Located in Birmingham, Ala., BioCryst develops novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases and viral infections.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.